Table 1.
Demographic, clinical and biochemical data of the patients.
| Characteristics | Total (n = 209) | no-IDH (n = 113) | IDH (n = 96) | p value |
|---|---|---|---|---|
| Age, years | 56.06 ± 13.87 | 52.63 ± 13.42 | 60.29 ± 13.31 | <.001 |
| Male | 118 (60.2%) | 81 (71.7%) | 37 (44.6%) | <.001 |
| Normalized ultrafiltration rate, ml/h/kg | 10.69 ± 4.14 | 9.65 ± 4.33 | 11.97 ± 3.50 | <.001 |
| IDWG, kg | 3.85 ± 1.58 | 3.43 ± 1.65 | 4.35 ± 1.33 | <.001 |
| Preserved residual kidney function | 41 (20.9%) | 35 (31%) | 6 (7.2%) | <.001 |
| Duration of dialysis, months | 30.57 ± 38.25 | 30.69 ± 41.11 | 30.41 ± 34.20 | .953 |
| Dry weight, kg | 58.67 ± 10.81 | 59.44 ± 10.16 | 57.73 ± 11.56 | .259 |
| spKt/Vurea | 1.53 ± 0.63 | 1.57 ± 0.71 | 1.48 ± 0.53 | .405 |
| BMI, kg/m2 | 22.32 ± 4.01 | 21.67 ± 3.68 | 23.20 ± 4.29 | .008 |
| Serum albumin, g/L | 39.14 ± 3.54 | 38.90 ± 3.78 | 39.42 ± 3.25 | .342 |
| Serum creatinine, μmol/L | 995.30 ± 286.09 | 974.28 ± 298.93 | 1022.81 ± 267.71 | .251 |
| Hemoglobin, g/L | 102 ± 25.24 | 99.28 ± 29.06 | 105.70 ± 18.39 | .745 |
| NT-proBNP, pg/mL | 5051.94 ± 5472.11 | 4660.82 ± 5266.30 | 5547.72 ± 5721.52 | .309 |
| iPTH, ng/L | 435.05 ± 462.15 | 393.52 ± 375.44 | 486.04 ± 548.57 | .187 |
| Serum β2MG, mg/L | 29.36 ± 12.59 | 30.58 ± 11.96 | 27.88 ± 13.24 | .176 |
| hs CRP, mg/L | 7.15 ± 12.26 | 7.62 ± 13.22 | 6.62 ± 11.15 | .590 |
| Predialysis-SBP, mmHg | 136.63 ± 17.67 | 139.27 ± 13.19 | 133.52 ± 21.46 | .019 |
| Predialysis-DBP, mmHg | 82.44 ± 10.81 | 84.47 ± 9.21 | 80.06 ± 12.05 | .003 |
| Postdialysis-SBP, mmHg | 125.46 ± 19.26 | 133.3 ± 15.9 | 116.14 ± 18.81 | <.001 |
| Postdialysis-DBP, mmHg | 78.45 ± 10.44 | 82.46 ± 8.37 | 73.68 ± 10.69 | <.001 |
| EF, % | 63.18 ± 9.25 | 63.22 ± 7.69 | 63.13 ± 11.47 | .962 |
| LADI, mm/m2 | 24.91 ± 4.17 | 24.55 ± 4.32 | 25.49 ± 3.91 | .238 |
| RWT | 0.46 ± 0.12 | 0.44 ± 0.80 | 0.49 ± 0.16 | .057 |
| LVMI, g/m2.7 | 47.33 ± 18.62 | 47.67 ± 16.07 | 46.92 ± 21.38 | .798 |
| Antihypertensive medication dosage, tablets | 2.39 ± 1.80 | 2.32 ± 1.80 | 2.54 ± 1.84 | .612 |
| Antihypertensive medication type | 1.98 ± 1.34 | 1.95 ± 1.34 | 2.04 ± 1.34 | .778 |
| Hypertension | 129 (65.8%) | 75 (66.4%) | 54 (65.1%) | .849 |
| Diabetes mellitus | 31 (15.8%) | 15 (13.3%) | 16 (19.3%) | .257 |
| Cardiovascular disease | 18 (9.2%) | 12 (10.6%) | 6 (7.2%) | .419 |
| Cerebrovascular disease | 3 (1.5%) | 1 (0.9%) | 2 (2.4%) | .393 |
Values are mean (SD) for continuous variables and % (n) for categorical variables.
IDWG: interdialytic weight gain; BMI: body mass index; NT-proBNP: N-terminal pro-B-type natriuretic peptide; iPTH: intact parathyroid hormone; β2MG: β2-microglobulin; hs-CRP: high-sensitive c-reactive protein; EF: ejection fraction; LADI: left atrium diameter index; RWT: relative wall thickness; LVMI: left ventricular mass index; Preserved residual kidney function: 24 h urine output over 100 mL.